Volpino Patrizia, Cavallaro Antonino, Cangemi Roberto, Chiarotti Flavia, De Cesare Alessandro, Fiori Enrico, Bononi Marco, Vigliarolo Rossana, Cangemi Vincenzo
First Department of General Surgery, University of Rome La Sapienza, Rome, Italy.
Anticancer Res. 2003 Nov-Dec;23(6D):4959-65.
Over the past few years, clinical, radiological and pathological classification of lung adenocarcinoma and its subtypes, particularly bronchioloalveolar carcinoma (BAC), has radically changed.
Out of a series of 384 non-small cell lung cancer (NSCLC) patients, submitted to surgical resection and followed-up in our Department from 1981 to 1999, the data of 151 adenocarcinomas (35 BAC and 116 non-BAC) were reviewed and analyzed for prognosis.
BAC and non-BAC series were similar in clinical and radiographic findings, type of resection and stage. Stage I was a dominant favorable prognostic factor (10-year survival: 58% of BAC, 41.2% of non-BAC), albeit associated with a significant risk of second primary metachronous lung tumor (10-year risk: 25% of BAC, 32% of non-BAC). Other independent prognostic factors were: absence of lymph node involvement for BAC and stage III-IV for non-BAC. In term of prognosis, advantages of BAC over non-BAC were fewer cases with lymph node involvement, increased presence of "well-differentiated" cells (p = 0.016) and lower incidence of a second primary metachronous tumor. Moreover BAC patients with a single nodule or mass also had a higher survival expectancy (mean survival: 77 months versus 56 for non-BAC). An unfavorable feature was the higher incidence of diffuse or multicentric radiological forms (p = 0.012). For both groups the presence of multiple or satellite nodules remain a diagnostic and surgical challenge: in BAC cases the evaluation of clonality is recommended.
在过去几年中,肺腺癌及其亚型,尤其是细支气管肺泡癌(BAC)的临床、放射学和病理学分类发生了根本性变化。
在1981年至1999年期间于我院接受手术切除并随访的384例非小细胞肺癌(NSCLC)患者中,回顾并分析了151例腺癌(35例BAC和116例非BAC)的数据以评估预后。
BAC组和非BAC组在临床和影像学表现、切除类型及分期方面相似。I期是主要的有利预后因素(10年生存率:BAC组为58%,非BAC组为41.2%),尽管伴有异时性第二原发性肺肿瘤的显著风险(10年风险:BAC组为25%,非BAC组为32%)。其他独立预后因素为:BAC组无淋巴结受累,非BAC组为III-IV期。就预后而言,BAC组相对于非BAC组的优势在于淋巴结受累病例较少、“高分化”细胞的比例增加(p = 0.016)以及异时性第二原发性肿瘤的发生率较低。此外,单发结节或肿块的BAC患者也有更高的预期生存率(平均生存期:BAC组为77个月,非BAC组为56个月)。一个不利特征是弥漫性或多中心放射学表现的发生率较高(p = 0.012)。对于两组而言,多个或卫星结节的存在仍然是诊断和手术的挑战:在BAC病例中,建议评估克隆性。